GT Biopharma announced updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE Trial an Investigational Immunotherapy for Refractory Cancers to be presented at ESMO Congress 2021
Today announced that Jeffrey Miller, MD, University of Minnesota Medical School, Professor of Medicine, Division of Hematology, Oncology and Transportation, will present a mini-oral presentation at the European Society for Medical Oncolology (ES
The mini-oral presentation will present a new positive phase 1 safety data, progress and preclinical data spanning the hematologic malignancies to solid tumors of - based on the phase one GTB-3550 The tri-specific Killer Engager TriKE program is currently in clinical development to treat acute acute leukemia (AML) and acute and severe acute myelodysplastic syndrome (MDS) relapsed/
Poster Presentation Details: Mini-oral Posting.
The following are: In anti-repressive patients with advanced myeloid malignancies, a novel paradigm exportable to solid tumors expressing Her2 or B7H3 (Abstract #4068).
Speaker: Jeffrey Miller, MD, was an MD.
Mini-oral session: An Investigational Immunotherapy (Channel 2) (chinal 2).
Presentation Time: September 17th, at 6:10 PM EST, At 6 p.m.
Mini-oral Presentation Number: 965MO for the southeastern hemisphere.
The abstract is available now on the ESMO website at www.esmo.org. At the beginning of the mini-oral session, the presentation will be available at the [presentations] section of The company's website at https://www.gtbiopharma.com/.
Recent announcements of the recent announcement The Company announced the launch of GTB-3650 into IND-enabling studies. With that, it plans to replace the ongoing phase 1 program with GTb-3550. GTB-3650 is a novel molecule based on camelid single-domain camel antibody technology with advantages that built upon the robust proof-of-concept data from the first generation TriKE program, GTF-3550.
GTB-3650, and its therapeutic and commercial advantages as well as the new era of the market, include::
- A single-domain antibody technology from a second generation camelid is based on syllables and single domain antibodies that holds several advantages over traditional IgG monoclonal antibodies.
- Strength and binding affinity improves strength and strength.
- Safety profile of a similar preclinical type, which does not include similar safety standards, also similar to preklinical safety profile, is compared to the same pre-clinic standard.
- Commercial manufacturing capabilities through arrangement with Cytovance.
- The Proprietary patented molecule is entirely owned by GT Biopharma, but which doesn't compete with GTB-3550, is owned in the ownership of GT biopharma.
About Camelid Antibodies About a smeary?
Camelid antibodies are camellid anticorps. Among mammals from the Camelidae family is single-domain antibodies (sdAbs) that include llamas, camels and alpacas. These animals produce two main types of antibodies. A conventional antibody is made up of two heavy and light chains. They also produce another antibody called "light" that is made up of only two heavy chains and no light chains. This is referred to as heavy chain IgG (hcIgg). The VHH region is a multi-synthetic antibody that does not contain the CH1 region. VHH antibodies, also known as single domain antibodies), only contain the VH region from the camelid antibody. Camelid antibodies have key characteristics: high affinity and specificity (quivalent to conventional antibodies), high thermostability, good solubility and strictly monomeric behavior, small size, relatively low production cost, genetic engineering flexibility, modular
GTB-3650 is the company's lead Tri-Specific Killer Engager TriKE, the third generation of the Company'. The first generation, GT B-3660 is a Trike-screen-driven Kill . Relapsed/refractory acute leukemia (AML) and the high-risk myelodysplastic syndrome (MDS) are currently under development.
About GT Biopharma, Inc.
GT Biopharma is a clinical-stage biopharmaceutical company that works with the pharmaceutical industry in the clinical stage, where we develop and commercialize immuno-oncology therapeutic products that use our proprietary TriKE proprietary proprietary ingredient. syllable / nythro cne a drgni el rit od msp NK cell engager platform. Our trike is our. s.r.o. The platform is designed to harness and improve the cancer-killing abilities of the natural killer cells of a patient's immune system. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE. y o c i d k n t r ets l ssrrstr. Technology is new. For more information, visit gtbiopharma.com.
Statements with a view to the future are based on the prospective perspective.
Upon evaluating such statements, you must consider the various risks and uncertainties that may be common in the future, such as: the risk of closing the potential transaction, the cost of a future transaction or the scope of our project, or
Nonetheless, the forward-looking statements reflect our current views regarding future events and are based on current financial, economic, scientific, and competitive data and information on existing business plans. There is no risk in any future reliance on our forward
As long as possible, these forward-looking statements will be subject to the safe harbor protection of the federal securities laws, such as the laws imposing on the subject of Section 27 of this Constitution, and without the exception of a copyright
The thief is a king. - s.r.l. The trademark is registered by GT Biopharma, Inc.
Investor Relations: David Castaneda [email protected] 414-351-9758 (414) 351-357-9558.
LifeSci AdvisorsCorey Davis, Ph.D.[email protected]212-915-2577.
SOURCE GT Biopharma, Inc.